Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2014

Open Access 01-12-2014 | Research

Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma

Authors: Ola H Nada, Naglaa S Ahmed, Hoda H Abou Gabal

Published in: Diagnostic Pathology | Issue 1/2014

Login to get access

Abstract

Background

Defects in Human Leukocyte Antigen (HLA) class I antigen expression and/or function in tumor cells have been extensively investigated, because of their potential role in the escape of tumor cells from T cell recognition and destruction. The researchers evaluated HLA class I expression in tumor tissue as a prognostic factor in osteosarcoma patients and as a predictor of their survival. This retrospective cohort study was conducted at the pathology laboratory of Ain Shams University Hospital, and Ain Shams University Specialized Hospital during the period between January 2009 and January 2012.

Methods

The researchers investigated HLA class I expression in primary osteosarcoma by immunohistochemistry using EMR8-5 mAbs. Furthermore, researchers evaluated the correlation between HLA class I expression and the clinicopathological status and outcome in formalin fixed paraffin embedded tissues from thirty six (36) patients with osteosarcoma.

Results

A high expression of HLA class I was detected in 18 (50) % of tumor samples examined; while tumors with low or negative expression represented 9 (25%) cases each. Data indicate that the overall survival rate of patients with tumors highly expressing HLA class I was significantly higher than those with low or negative expression.

Conclusion

Down-regulation of class I antigen expression is associated with features of aggressive disease and a poorer prognosis. Therefore, it is imperative to identify HLA as a prognostic factor at the time of diagnosis to detect chemotherapy-resistant tumors and to generate a modified treatment regimen.

Virtual slides

The virtual slides for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1159334857109547​.
Appendix
Available only for authorised users
Literature
1.
Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for Pediatric osteosarcoma. Oncologist. 2004, 9 (4): 422-441. 10.1634/theoncologist.9-4-422.PubMedCrossRef
2.
Fagioli F, Biasin E, Mereuta OM, Muraro M, Luksch R, Ferrari S, Aglietta M, Madon E: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant. 2008, 41 (Suppl 2): S131-S134.PubMedCrossRef
3.
Haydon RC, Luu HH, He TC: Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res. 2007, 454: 237-246.PubMedCrossRef
4.
Kansara M, Thomas DM: Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007, 26 (1): 1-18. 10.1089/dna.2006.0505.PubMedCrossRef
5.
Ritter J, Bielack SS: Osteosarcoma. Ann Oncol. 2010, 21 (7): vii: 320-vii: 325.
6.
Sakamoto A, Iwamoto Y: Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials. 2008, 3 (3): 228-231. 10.2174/157488708785700267.PubMedPubMedCentralCrossRef
7.
Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Redini F: Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther. 2007, 7 (2): 169-181. 10.1586/14737140.7.2.169.PubMedCrossRef
8.
Klein MJ, Siegal GP: Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol. 2006, 125: 555-581. 10.1309/UC6KQHLD9LV2KENN.PubMedCrossRef
9.
Fletcher C, Unni K, Mertens F: Conventional Osteosarcoma. Pathology and Genetics of Tumors of Soft Tissue and Bone. 2013, Lyon, France: IARC Press, 4
10.
Chou AJ, Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006, 6 (7): 1075-1085. 10.1586/14737140.6.7.1075.PubMedCrossRef
11.
Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defaschelles AS, Hartmann O: Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome–the French pediatric experience. Cancer. 2005, 104 (5): 1100-1109. 10.1002/cncr.21263.PubMedCrossRef
12.
Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006, 32 (6): 423-436. 10.1016/j.ctrv.2006.05.005.PubMedCrossRef
13.
14.
Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, Van Glabbeke M, Machin D: Randomized trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997, 350 (9082): 911-917. 10.1016/S0140-6736(97)02307-6.PubMedCrossRef
15.
Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P: Children’s Oncology Group. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children’s Oncology Group. J Clin Oncol. 2007, 25 (15): 2057-2062. 10.1200/JCO.2006.07.7776.PubMedCrossRef
16.
Tan ML, Choong PF, Dass CR: Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther. 2009, 8 (2): 106-117. 10.4161/cbt.8.2.7385.PubMedCrossRef
17.
Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005, 23 (3): 559-568.PubMedCrossRef
18.
Carsi B, Rock MG: Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res. 2002, 397: 53-61.PubMedCrossRef
19.
Heck RK, Stacy GS, Flaherty MJ, Montag AG, Peabody TD, Simon MA: A comparison study of staging systems for bone sarcomas. Clin Orthop Relat Res. 2003, 415: 64-71.PubMedCrossRef
20.
Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006, 106 (5): 1154-1161. 10.1002/cncr.21724.PubMedCrossRef
21.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002, 20 (3): 776-790. 10.1200/JCO.20.3.776.PubMedCrossRef
22.
Grimer RJ, Taminiau AM, Cannon SR: Surgical Subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma. J Bone Joint Surg (Br). 2002, 84 (3): 395-400. 10.1302/0301-620X.84B3.12019.CrossRef
23.
Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, Forni C, Versari M: Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep. 2002, 9 (1): 171-175.PubMed
24.
Kim MS, Lee SY, Lee TR, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG: Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009, 20 (5): 955-960. 10.1093/annonc/mdn723.PubMedCrossRef
25.
Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, Liu X, Mankin H, Duan Z: The kinase Mirk is a potential therapeutic target in osteosarcoma. Carcinogenesis. 2010, 31 (4): 552-558. 10.1093/carcin/bgp330.PubMedPubMedCentralCrossRef
26.
Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M: HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci. 2007, 98 (9): 1424-1430. 10.1111/j.1349-7006.2007.00558.x.PubMedCrossRef
27.
Homma I, Kitamura H, Torigoe T, Tanaka T, Sato E, Hirohashi Y, Masumori N, Sato N, Tsukamoto T: Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy. Cancer Sci. 2009, 100 (12): 2331-2334. 10.1111/j.1349-7006.2009.01329.x.PubMedCrossRef
28.
Bubeník J: MHC class I down-regulation: tumor escape from immune surveillance? (Review). Int J Oncol. 2004, 25 (2): 487-491.PubMed
29.
Hosch SB, Izbicki JR, Pichlmeier U, Stoecklein N, Niendorf A, Knoefel WT, Broelsch CE, Pantel K: Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer. 1997, 74: 582-587. 10.1002/(SICI)1097-0215(19971219)74:6<582::AID-IJC4>3.0.CO;2-Q.PubMedCrossRef
30.
Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999, 154 (3): 745-754. 10.1016/S0002-9440(10)65321-7.PubMedPubMedCentralCrossRef
31.
Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S: HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005, 11 (1): 67-72.PubMed
32.
Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG: Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer. 2006, 118 (1): 6-10. 10.1002/ijc.21303.PubMedCrossRef
33.
Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T: Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol. 2007, 177 (4): 1269-1272. 10.1016/j.juro.2006.11.082.PubMedCrossRef
34.
Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H: Downregulation of HLA Class I molecules in the tumor is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2008, 99 (9): 1462-1467. 10.1038/sj.bjc.6604715.PubMedPubMedCentralCrossRef
35.
Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, Shinchi H, Koriyama C, Ueno S, Yoshinaka H, Natsugoe S: Clinical implication of HLA class I expression in breast cancer. BMC Cancer. 2011, 11: 454-10.1186/1471-2407-11-454.PubMedPubMedCentralCrossRef
36.
Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E: Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res. 2005, 65 (9): 3937-3941. 10.1158/0008-5472.CAN-04-4621.PubMedCrossRef
37.
Kamarashev J, Ferrone S, Seifert B, Böni R, Nestle FO, Burg G, Dummer R: TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer. 2001, 95 (1): 23-28. 10.1002/1097-0215(20010120)95:1<23::AID-IJC1004>3.0.CO;2-4.PubMedCrossRef
38.
Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG: Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005, 117 (2): 248-255. 10.1002/ijc.21163.PubMedCrossRef
39.
Seliger B: Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother. 2008, 57 (11): 1719-1726. 10.1007/s00262-008-0515-4.PubMedCrossRef
40.
Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today. 1997, 18: 89-95. 10.1016/S0167-5699(96)10075-X.PubMedCrossRef
41.
Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, Kanaseki T, Hasegawa T, Sato N: Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int. 2012, 62 (5): 303-308. 10.1111/j.1440-1827.2012.02789.x.PubMedCrossRef
42.
Sato N, Hirohashi Y, Tsukahara T, Kikuchi T, Sahara H, Kamiguchi K, Ichimiya S, Tamura Y, Torigoe T: Molecular pathological approaches to human tumor immunology. Pathol Int. 2009, 59 (4): 205-217. 10.1111/j.1440-1827.2009.02353.x.PubMedCrossRef
43.
Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T: HLA-class I expression in gastric cancer. J Surg Oncol. 2008, 97 (7): 605-608. 10.1002/jso.21029.PubMedCrossRef
44.
Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T, Yamashita T, Sato N: Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006, 97 (12): 1374-1380. 10.1111/j.1349-7006.2006.00317.x.PubMedCrossRef
45.
Zhu H, Tang J, Tang M, Cai H: Up regulation of SOX9 in osteosarcoma and its association with tumor progression and patients’ prognosis. Diagn Pathol. 2013, 8 (1): 183-10.1186/1746-1596-8-183.PubMedPubMedCentralCrossRef
46.
Liang X, Wang D, Wang Y, Zhou Z, Zhang J, Li J: Expression of aurora kinase A and B in chondrosarcoma and its relationship with the prognosis. Diagn Pathol. 2012, 7: 84-10.1186/1746-1596-7-84.PubMedPubMedCentralCrossRef
47.
Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U: Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984, 2 (6): 617-624.PubMed
Metadata
Title
Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma
Authors
Ola H Nada
Naglaa S Ahmed
Hoda H Abou Gabal
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-9-72

Other articles of this Issue 1/2014

Diagnostic Pathology 1/2014 Go to the issue

Methodology

Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas

Research

Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings

Research

Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: a descriptive study

Research

A novel model for Ki67 assessment in breast cancer

Software

Automated Selection of Hotspots (ASH): enhanced automated segmentation and adaptive step finding for Ki67 hotspot detection in adrenal cortical cancer

Case Report

Malignant adenomyoepithelioma combined with adenoid cystic carcinoma of the breast: a case report and literature review